Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Century Therapeutics, Inc.IPSC · Entity 5739 | Director | June 12, 2025 | June 16, 2025 |
| LENZ Therapeutics, Inc.GRPH · Entity 6475 | Director | July 19, 2023 | July 21, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Century Therapeutics, Inc.
Report date June 12, 2025 · Filed June 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.60 · Expires 2035-06-12 | Direct | 44,000 |
Reported balance
After 2025-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-12 · Grant · Acquired 44,000 · Balance 44,000 F1: The option vests on the earlier of (a) June 12, 2026, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests on the earlier of (a) June 12, 2026, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date.
LENZ Therapeutics, Inc.
Report date July 19, 2023 · Filed July 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.72 · Expires 2033-07-18 | Direct | 20,000 |
Reported balance
After 2023-07-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-07-19 · Grant · Acquired 20,000 · Balance 20,000 F1: The shares subject to such option vest in full on the earlier of (i) the one-year anniversary of the grant date or on (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to such option vest in full on the earlier of (i) the one-year anniversary of the grant date or on (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Pandion Therapeutics, Inc.
Report date April 01, 2021 · Filed April 01, 2021
Section 16 reporting ended · disclosed 2021-04-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2030-07-16 | Direct | 0 |
Reported balance
After 2021-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-04-01 · Disposition to issuer · Disposed 13,997 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated February 24, 2021, among Pandion Therapeutics, Inc. (the "Company"), Merck Sharp & Dohme Corp. ("Merck") and Panama Merger Sub, Inc. ("Merger Sub"), Merger Sub commenced a tender offer (the "Offer") to purchase all outstanding Company common stock for the price of $60.00 per share in cash (the "Offer Price"). On April 1, 2021, the Offer consummated, after which Merger Sub merged with and into the Company (the "Merger") and the Company became a wholly owned subsidiary of Merck. At the consummation of the Offer and the Merger, respectively, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Offer Price and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were cancelled and converted automatically into the right to receive the Offer Price. F3: Disposed of pursuant to the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option. F2: All options were vested and exercisable as of immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated February 24, 2021, among Pandion Therapeutics, Inc. (the "Company"), Merck Sharp & Dohme Corp. ("Merck") and Panama Merger Sub, Inc. ("Merger Sub"), Merger Sub commenced a tender offer (the "Offer") to purchase all outstanding Company common stock for the price of $60.00 per share in cash (the "Offer Price"). On April 1, 2021, the Offer consummated, after which Merger Sub merged with and into the Company (the "Merger") and the Company became a wholly owned subsidiary of Merck. At the consummation of the Offer and the Merger, respectively, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Offer Price and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were cancelled and converted automatically into the right to receive the Offer Price.
F2: All options were vested and exercisable as of immediately prior to the Effective Time.
F3: Disposed of pursuant to the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2025 Filed Jun 16, 2025 22:25 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantStock Option (right to buy) · Derivative | 44,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001062993-25-011785 · form4.xml · derivative · entry 1 Carlo Rizzuto · CIK 0001817033 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2035-06-12 F1 · derivative.exercise_date: The option vests on the earlier of (a) June 12, 2026, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 20:49 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantStock Option (right to buy) · Derivative | 44,000 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0001062993-24-012902 · form4.xml · derivative · entry 1 Carlo Rizzuto · CIK 0001817033 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2034-06-20 F1 · derivative.exercise_date: The option vests on the earlier of (a) June 20, 2025, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| July 19, 2023 Filed Jul 21, 2023 17:05 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.72 | $0.00 |
DisclosureSEC source: 0001209191-23-043131 · doc4.xml · derivative · entry 1 Carlo Rizzuto · CIK 0001817033 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-07-18 F1 · derivative.exercise_date: The shares subject to such option vest in full on the earlier of (i) the one-year anniversary of the grant date or on (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date. Read SEC document |
| June 27, 2023 Filed Jun 29, 2023 20:23 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantStock Option (right to buy) · Derivative | 44,000 | $0.00 Strike: $3.19 | $0.00 |
DisclosureSEC source: 0001062993-23-014173 · form4.xml · derivative · entry 1 Carlo Rizzuto · CIK 0001817033 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2024-06-27 F1 · derivative.exercise_date: The option vests on the earlier of (a) June 27, 2024, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 21, 2022 Filed Jun 22, 2022 17:36 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0001209191-22-038730 · doc4.xml · derivative · entry 1 Carlo Rizzuto · CIK 0001817033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-20 F1 · derivative.exercise_date: The shares subject to such option vest in full on the earlier of (i) the one-year anniversary of the grant date or on (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 20:21 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantStock Option (right to buy) · Derivative | 19,872 | $0.00 Strike: $8.56 | $0.00 |
DisclosureSEC source: 0001062993-22-014653 · form4.xml · derivative · entry 1 Carlo Rizzuto · CIK 0001817033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,872 Underlying: Common Stock · 19,872 shares Expires 2032-06-09 F1 · derivative.exercise_date: The option vests on the earlier of (a) June 9, 2023, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 20:00 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000899243-21-026342 · doc4.xml · derivative · entry 1 Carlo Rizzuto · CIK 0001817033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-06-23 F1 · derivative.exercise_date: 1/36th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of June 24, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:32 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantOption (right to buy) · Derivative | 39,744 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001192482-21-000558 · edgar.xml · derivative · entry 1 Carlo Rizzuto · CIK 0001817033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,744 Underlying: Common Stock · 39,744 shares Expires 2031-06-17 F1 · derivative.exercise_date: The option vests in 36 equal monthly installments, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| April 01, 2021 Filed Apr 1, 2021 19:38 UTC | Pandion Therapeutics, Inc. PAND · Entity 11788 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 13,997 | Not disclosed Strike: $18.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-014436 · doc4.xml · derivative · entry 1 Carlo Rizzuto · CIK 0001817033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,997 shares Expires 2030-07-16 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated February 24, 2021, among Pandion Therapeutics, Inc. (the "Company"), Merck Sharp & Dohme Corp. ("Merck") and Panama Merger Sub, Inc. ("Merger Sub"), Merger Sub commenced a tender offer (the "Offer") to purchase all outstanding Company common stock for the price of $60.00 per share in cash (the "Offer Price"). On April 1, 2021, the Offer consummated, after which Merger Sub merged with and into the Company (the "Merger") and the Company became a wholly owned subsidiary of Merck. At the consummation of the Offer and the Merger, respectively, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Offer Price and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were cancelled and converted automatically into the right to receive the Offer Price. F3 · price: Disposed of pursuant to the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option. F2 · derivative.exercise_date: All options were vested and exercisable as of immediately prior to the Effective Time. Read SEC document |
| July 17, 2020 Filed Jul 21, 2020 19:37 UTC | Pandion Therapeutics, Inc. PAND · Entity 11788 | GrantStock Option (right to buy) · Derivative | 13,997 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0000899243-20-019870 · doc4.xml · derivative · entry 1 Carlo Rizzuto · CIK 0001817033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,997 Underlying: Common Stock · 13,997 shares Expires 2030-07-16 F1 · derivative.exercise_date: This option award was granted on July 17, 2020. The shares underlying the award vest in equal monthly installments following July 17, 2020 through July 17, 2023, subject to the reporting person's continued service on each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.